2010;52:825-33. 833
e1-e2.
238. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM,
Flynn TC, et al. Warfarin improves the outcome of infrainguinal
vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:
446-57.
239. Jackson MR, Johnson WC, Williford WO, Valentine RJ, Clagett GP.
The effect of anticoagulation therapy and graft selection on the
ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial. J Vasc Surg
2002;35:292-8.
240. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant
drugs for prevention of restenosis/reocclusion following peripheral
endovascular treatment. Cochrane Database Syst Rev 2012;8:
CD002071.
241. Koppensteiner R, Spring S, Amann-Vesti BR, Meier T, Pfammatter T,
Rousson V, et al. Low-molecular-weight heaprin for prevention of
restenosis after popliteal percutaneous transluminal angioplasty: a
reandomized controlled trial. J Vasc Surg 2006;44:1247-53.
242. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S.
Cilostazol reduces restenosis after endovascular therapy in patients
with femor0popliteal lesions. J Vasc Surg 2008;48:144-9.
243. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Tanaka M,
et al. Effects of oral cilostazol 100 mg BID on long-term patency
after percutaneous transluminal angioplasty in patients with

40S Conte and Pomposelli et al

femoropopliteal disease